Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  4.80 4.95% 101.80 1,520,743 16:35:18
Bid Price Offer Price High Price Low Price Open Price
98.00 101.00 108.50 95.50 95.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.94 -29.19 -10.57 259
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:51 O 21,000 101.80 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta Forums and Chat

Date Time Title Posts
25/6/202212:50Avacta – Innovative and Disruptive Technologies for Global Health Markets46,296
23/5/202208:05Covid-19. Ten Minute Test. Gamechanger!!19,641
23/2/202207:14CV And The Deep State228
18/2/202212:51Covid-19. Ten Minute Test. Gamechanger!!78
13/1/202209:16avct The Fall!!!119

Add a New Thread

Avacta (AVCT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
25/6/2022
09:20
Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 97p.
Avacta Group Plc has a 4 week average price of 91p and a 12 week average price of 59p.
The 1 year high share price is 196p while the 1 year low share price is currently 38.50p.
There are currently 254,901,919 shares in issue and the average daily traded volume is 1,496,941 shares. The market capitalisation of Avacta Group Plc is £259,490,153.54.
25/6/2022
12:06
tickboo: Firstly and most significantly, the CEO started off with:"I'll reiterate what I said at the prelims, it's going VERY well." (also stated in the pres, p.5 ??).Following 5 months of silence, it was vital we were told that. Evidently, no news is indeed, good news!The panic sell-off, mid-AGM, was clearly due to the news that P1a would not complete until late Q3 - it had previously been pitched as "middle of the year".Reading between the lines, I think C2 has had 1-2 patient withdrawals (which may come about for obvious reasons).AS reiterated a poignant point, that these patients are terminal - they're acting altruistically, to improve medicine for future generations.What's a 3-month delay in trial, in comparison?In any event, it was suggested that C3 will be starting shortly (provided the SDMC is happy with the completed C2, and approves the dose escalation).The fact that #AVCT already knows the exact planned dosing level for C3 (being 150mg/m2), suggests that SDMC is ready to greenlight it (waiting on the completion of the final patient in C2, perhaps?)Despite the delay, mgmt reiterated that they have budgeted for four cohorts (and cash besides to see AVCT well into 2023). Whether or not there will be a fourth cohort is another matter - depending of course on how the patients of C3 fare.The maximum tolerated dose was referenced numerous time - or rather, the distinct possibility that it may not be found at all. Rather, the clinicians may just decide upon a recommended phase 2 dose (RP2D) - which would likely be the dosing level that C3 or C4 receive.To put that into perspective:C3's intended dosing level (150 mg/m2) is the equivalent to 101 mg/m2 of standard doxorubicin. Dox is usually administered in doses of around 60 mg/m2.So even with an almost 70% increase (equivalent) in dose, #AVCT thinks it possible that there will be no dose limiting toxicities. And if there's a C4? Mgmt suggested it could be in the region of 165 mg/m2 (but stressed that was a guess) - which would be an 85%+ increase.It is abundantly clear that at least one half of the challenge - improved safety and tolerability - hasbeen achieved.But, as I explain below (pp.8-12), the second half of the challenge is equally critical: namely, activation of the dox in the tumor micro-environment.The near- to medium-term bull thesis for #AVCT rests on this bit of info.https://aimchaos.files.wordpress.com/2022/04/avacta-group-precision-platform-3.pdfSure enough, mgmt refused to comment on it at all!We only had this:"Have you received any biopsies yet?""I am very confident that we will have biopsy data when we put together the whole package, yes."Bear in mind that it's not a blinded trial. There's no placebo.AVCT will be receiving info on a weekly (more likely, daily) basis.My own guess is that they have received at least 1-2 biopsies now (they had put assays in place over 10 weeks ago), and they're very happy with what they're seeing. But as ever, we must await that full data readout.Another indicator that activation at the TME is occurring:The CEO suggested that the indications for P1b will be STS and ovarian (although to note, it's not concrete yet). The fact that they have already picked these two, is telling.AVCT also thinks it could move into a pivotal phase 2 trial for AVA6K, in the middle of next year (a bit punchy, in my view, but good to hear that they think things can move quickly, post P1a).P1b should be considerably quicker than P1a - it'll be 20 or so patients for each tumor type, but with patients not having to be staggered. 8 hospitals will be up and running by then - recruitment should not be an issue.AS also mentioned that one of the US hospitals is a specialist site for STS - so will be key for P1b. As @RAH00084 has just pointed out, it would seem that said hospital could well be Memorial Sloane Kettering.I tried to push about whether the AVA6K data room was open to potential licensees / suitors. AS was having absolutely none of it, but did acknowledge that THEORETICALLY, of course such parties could examine the existing data - under NDA.After the AGM, a few of us were speaking to AS about FAP, and he reiterated that FAP in general is a very hot topic right now. Everyone else is trying to use it as a tumor biomarker.IF #AVCT generates positive data in P1a, demonstrating that they can use FAP to cleave, then he suggested there could be a lot of interest in the company.I guess we shall find out in a few months.More generally, I'm extremely relaxed now about holding @avacta in size, despite the horrendous wider market conditions.Despite #AVCT's lofty market cap compared to other P1-stage listed biotechs, its globally unique (and protected, via patents) platform in preCISION gcould give it a total address market of many tens of $ billions, pa.The next few months will be critical in providing proof of concept for the whole platform.In that time, we should get 1, maybe 2, more dose escalationsWith the 'delay' now out in the open and the traders having exited, I'm optimistic of some stability in the share price and a decent run up to the P1a readout (slow and steady, please!).Was very happy to add to our holdings this AM at sub 100p (only a few as absurdly overweight already).But I am more convinced than ever that #AVCT is a once-in-a-decade opp.
25/6/2022
10:46
pwhite73: There is no such thing as overvaluation or undervaluation in isolation. Shares are worth what people are prepared to buy and sell them for. You can't just say because NCYT has X market cap with Y revenues/profits it means AVCT must be -X market because of -Y revenues/profits. What you're missing is expectations in a share price. On the contrary I would say AVCT is well undervalued if AVA6000 can even remotely do what AS claims it can. I personally do not belief that AVA6000 has any efficacy whatsoever hence why the PK results will not be released this summer nor do I belief they will be released in the Autumn, at the end of the year or anytime in the foreseeable future. On this basis I believe AVCT is about 80% overvalued. Keeping HMS Avacta afloat by dangling billion dollar contracts in the face of PI investors is what Captain AS has been doing successfully for 18 years and all credit to him. He done it with the Affimers which failed. He done it with the Covid LFT which failed and now he plays his last card which is AVA6000. Unfortunately with the world entering recession and less capital available for pipedreams Avacta are drinking in the Last Chance saloon. The share price will sharply collapse and sooner than many posters here think.
25/6/2022
10:16
oilandgasman1: Avct yes may have smaller liabilities but the value here currently is just overvalued to a big extentLook at poor ncyt, they had profits last year excluding the dhsc but yet their pe ratio is low and they have cash balances and the share price still strugglesAvct may have big backers but it is being pumped to a point by the twitter crew are now delusional with their "research" Remember the "researchers" onOdx and dddd
25/6/2022
09:27
pwhite73: ACVT and DDDD are two different kinds of pharma companies in two different kinds of trouble. DDDD had £13 million of liabilities that could not be serviced on demand. So has been placed into administration. AVCT liabilities are only £5 million that can easily be serviced from its cash balance but it has operating losses it can no longer service (£29m Y/E 31/12/2021). However the company has taken drastic measures to reduce costs like closing the Cambridge laboratory and merging it into a science theme park in London. They have sold the Animal Health division. They have discontinued the Covid LFT diagnostic division although they'll never admit it. They are sponsoring AVA6000 from only one hospital instead of the planned six. I see no threat of this company going into administration. The danger that will befall shareholders is a complete collapse in the share price when/if the Phase I PK results are ever released. This is why the results have been kicked into the long grass to make way for the next placing.
19/6/2022
13:07
tickboo: They have cash until next spring. That said I expect them to either raise cash through a shares issue or through a licensing or partnership deal but this autumn. AVA6000 data is expected in August and if anything as good as pre-clinical the share price will be at all time highs. The CEO has implied a licensing or partnership deal more likely and if the data is good there will be a decent number of suitors and a good deal for shareholders.Clearly if data is poor the share price will fall and fall a lot! Any bad news/data we would have had an RNS so not far from a year into the trial no news is good news.I hope you have not got a short old chap.
27/4/2022
10:44
pwhite73: FilthyPoor - "So, Whitey, first you argue that AVA 6000 does not work" That is my personal opinion based on the experience of investing and losing money in biotech stocks. FilthyPoor - "you've moved on to say that they haven't demonstrated how it works and that's what "the market" wants to know." That's why the share price is not making any traction as it heads towards the summer PK updates. FilthyPoor - "The market doesn't give a toss how it works, just whether it works or not." Yes it does because if the share price is ever to reflect and sustain the market cap of a company progressing towards a new cancer prodrug it must ultimately attract the attention of institutions that invest in biotech stocks.
23/4/2022
12:54
pwhite73: Irpy - There is no contradiction in my post at all. The government had set a deadline on positive news for the LFT way back in July 2021. Therefore Jupiter and Bronte were assured that the LFT would fail as they both knew including myself that the use of Affimers would not meet the criteria set by the DHSC/Porton Down/UKHSA. Eventually as predicted by myself many months ago Avacta were forced to come clean on the LFT which resulted in a collapse of the share price from a high of 290p during the pandemic to a low of 38p at one point. The LFT is now out of the way so Avacta is in total control of its news flow not the government. At the moment it is too risky to be shorting Avacta because they can issue positive news from the 101 vacuous collaborations they have all over the world that could send the share price soaring. However as the summer approaches and the market is awaiting and refocused on the Phase I study you will see the share price begin to slide. This is when shorters are likely to return perhaps including Jupiter and Bronte. Furthermore the company is burning through £2 million per month. When you guys are gearing up for a multi-bagger come June/July that is when the share price will collapse again. I don't post so much here now because I have been proven right and there really is nothing to discuss until the PK results are released. I am a friend of Avacta shareholders not an enemy.
23/4/2022
10:44
pwhite73: Jupiter and Bronte have had to close their shorts for there is no more bad news to come. Avacta never ever releases bad news, everything is always going exactly to plan. Unfortunately it was the government/DHSC/UKSA that forced their hand on the LFT. Jupiter and Bronte shorts were riding on the back off the failed LFT for which I would imagine they made a killing. With shorts closing this does not mean the share price will continue to rise and rise. The reality that AVA6000 is pure fantasy will slowly begin to seep through over the course of the summer. The company will try to mitigate this with positive news from its joint ventures across the globe but they will not be sufficient to halt the eventual slide and collapse in the share price as it needs to urgently place stock to keep this cash guzzling, expensive, non-revenue generating, non-profit organisation on the road. As part of its cost cutting drive it has been forced to sell the Animal Health division, close down the Cambridge therapeutic laboratories and shack up with Imperial College London at its White City location. You've been warned.
14/4/2022
17:43
pwhite73: Rajraj b - "This will continue to rise over the next few weeks now" Irpy - "Lots of news to come" The company has ditched the LFT so are in control of their own therapeutic news flow. The danger for the share price is that the market will in turn begin to focus on their therapeutic pipeline and ask questions. If institutions hold the view that I do you may see the share price start drifting back as shorts are opened under 0.50%. I have stated before AVA6000 has now gone past pre-clinical trials and are in clinical trials yet there are no scholarly articles written by their peers on the drug. Both the poster presentation and AS stated that preCISION prevents leakage of DOX but from a chemical point of view how is it doing this? The answer is above me and every other poster here but not above post-graduates and medics in the pharmacology industry. How is AVA6000 successful where all others have failed?
07/4/2022
11:48
tickboo: Exactly and it was the only home-use LFT approved in EU. PWhite profile has 4-5 users and they do not have the discipline to confer re their stupid claims and lies. Quite comical and they clearly think they are able to affect sentiment and the share price hence all the posts. Pathetic. Part of TW massive. On this occasion they must have been really confident in their short with the share price increase before results RNS. I assume that is why they are posting so frequently. JakNife, as I said, a good lad knows TW well so I hope he did not follow TW and open a short on this.Am looking forward to the pre-clinical presentation.
Avacta share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 20:21:28